Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Akcea Therapeutics, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Akcea Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Akcea Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is AKCA. The reporting company's CIK number is 1662524.
The total value of stock buying since 2005 is $224,999,987.
The total value of stock sales since 2005 is $590,852.
The total value of stock option exercises since 2005 is $119,141.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2019-03-06||Soteropoulos Paula (Chief Executive Officer)||Sale||18,386||32.14||590,852|
|2019-03-06||Soteropoulos Paula (Chief Executive Officer)||Option Ex||18,386||6.48||119,141|
|2018-04-17||Ionis Pharmaceuticals Inc (10% Owner)||Buy||10,666,666||18.75||199,999,987|
|2017-07-19||Ionis Pharmaceuticals Inc (10% Owner)||Buy||3,125,000||8.00||25,000,000|
Insider trading activities including stock purchases, stock sales, and option exercises of AKCA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Akcea Therapeutics, Inc. (symbol AKCA, CIK number 1662524) see the Securities and Exchange Commission (SEC) website.